Central Obesity
Conditions
Brief summary
In this study, a 8-week, single blinded, randomized controlled clinical trial will be conducted to examine the efficacy and safety of body acupuncture in the treatment of central obesity in Hong Kong.
Detailed description
This is a pilot single-blind, randomized, sham-controlled trial. 168 central obesity patients will be randomly assigned to acupuncture group or control group. The duration of the treatment will be 8 weeks with 2 session per week and the follow-up period will be 2 weeks.
Interventions
OTHERacupuncture
Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points. We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes.
Sponsors
Princess Margaret Hospital, Hong Kong
Hong Kong Baptist University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Subjects of both groups will be randomly assigned to receive either electro-acupuncture or control (sham) treatment. For randomization, simple, complete non-sequential random numbers will be generated in advance by a computer program in a block of four, and kept by the principal investigator. After a patient's eligibility is confirmed, a randomization number which corresponds to the group allocation will be provided to the acupuncturist by the PI. This arrangement will ensure that the clinical assessor and participants are blinded to the allocation.
Intervention model description
single-blinded, randomized, sham-controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Patients who meet all of the following criteria are defined as eligible participants: men and women aged between 18 and 65 years old; BMI ≥ 25 kg/m2; central obesity, defined as WC of ≥ 90 cm in men and ≥ 80 cm in non-pregnant women according to ICD-10 \[24\]; not receiving any other weight control measures or any medical and/or drug history in last 3months.
Exclusion criteria
Patients who meet any of the following criteria should be excluded from the study: endocrine diseases, including thyroid disorder, pituitary disorder, sex gland disorder, etc.; heart diseases, including arrhythmia, heart failure, myocardial infarction, patients with pacemaker; allergy and immunology diseases; bleeding tendency; pregnant or lactating women; impaired hepatic or renal function; stroke or unable to exercise.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in waist circumference | 0,1,2,3,4,5,6,7,8, 11, 15,18, 21, 24 weeks | Waist circumference will be measured around the abdomen at the level of the umbilicus (belly button). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in hip circumference | 0,1,2,3,4,5,6,7,8,9,11,15,18, 21, 24 weeks | hip circumference measured at the level of maximum posterior extension of the buttocks |
| Adverse events after treatment and follow up | 0,1,2,3,4,5,6,7,8, 15,18, 21, 24 weeks | Adverse events of acupuncture treatment will be assessed using the Treatment Emergent Symptom Scale (TESS) and would be evaluated during the whole procedure, as well as laboratory tests (whole blood counts, renal and liver functions) if needed. All clinical adverse events will be recorded in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study. |
| Changes in waist-to-hip circumference ratio | 0,1,2,3,4,5,6,7,8, 15,18, 21, 24 weeks | waist-to-hip ratio is the dimensionless ratio of the circumference of the waist to that of the hips. This is calculated as waist measurement divided by hip measurement ( W ÷ H ). |
| Changes in Body Mass Index | 0,1,2,3,4,5,6,7,8, 15,18, 21, 24 weeks | Body Mass Index is a simple calculation using a person's height and weight. The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared. |
| Changes in body fat percentage | 0,1,2,3,4,5,6,7,8, 15,18, 21, 24 weeks | The body fat percentage (BFP) of a human or other living being is the total mass of fat divided by total body mass, multiplied by 100. Body fat percentage will be measured by Omron Karada Scan HBF-701. |
| Changes in total cholesterol (TC), triglyceride (TG) and fasting blood glucose (FBG) | 0, 8 weeks | Total cholesterol (TC), triglyceride (TG) and fasting blood glucose (FBG) will be measured before and after the 8-week treatment. |
Countries
Hong Kong
Outcome results
None listed